| Biomarker ID | 883 |
| PMID | 22371711 |
| Year | 2012 |
| Biomarker | ANRIL; H19; PCA3; MALAT1 |
| Biomarker Basis | Expression Based |
| Biomolecule | LncRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Metastatic Vs Normal |
| Type of Biomarker | Diagnostic |
| Cohort | 131 primary prostate cancer, 29 normal adjacent, and 19 metastatic specimens were downloaded from GEO Omnibus at GSE21034. (Dataset was: Memorial Sloan–Kettering Cancer CenterProstate Oncogenome Project) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | CDKN2B-AS1, H19, PCA3, MALAT1 |